KZIAKazia Therapeutics
KZIA
Kazia Therapeutics6,694
Mkt Cap
$141.81MVolume
105,463.0052W High
$17.4052W Low
$3.49PE Ratio
-1.83KZIA Fundamentals
Price
$12.43Prev Close
$12.51Open
$12.8650D MA
$10.64Beta
1.37Avg. Volume
291,525.05EPS (Annual)
-$12.23P/B
4.58$4.28
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer PR Newswire SYDNEY, May 26, 2026 Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging...
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform Kazia Therapeutics Strengthens Scientific...
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug...
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear...
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Kazia Therapeutics Reports...
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics to Participate in J.P. Morgan Healthcare...
Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?
read more...
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Kazia Therapeutics Regains Full Nasdaq Listing Compliance Kazia Therapeutics Regains Full Nasdaq Listing Compliance PR Newswire SYDNEY, Dec. 22, 2025 Restoration of Nasdaq compliance follows $50...
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations...
<
1
2
...
>
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest KZIA News
ViewKazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
Advertisement|Remove ads.